JP2010521139A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010521139A5 JP2010521139A5 JP2009549848A JP2009549848A JP2010521139A5 JP 2010521139 A5 JP2010521139 A5 JP 2010521139A5 JP 2009549848 A JP2009549848 A JP 2009549848A JP 2009549848 A JP2009549848 A JP 2009549848A JP 2010521139 A5 JP2010521139 A5 JP 2010521139A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- tshr
- thyroid
- antagonist
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000003911 Thyrotropin Receptors Human genes 0.000 claims 32
- 108090000253 Thyrotropin Receptors Proteins 0.000 claims 32
- 238000000034 method Methods 0.000 claims 20
- 210000001685 thyroid gland Anatomy 0.000 claims 16
- 239000005557 antagonist Substances 0.000 claims 14
- 102000011923 Thyrotropin Human genes 0.000 claims 11
- 108010061174 Thyrotropin Proteins 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000004936 stimulating effect Effects 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 6
- 206010020850 Hyperthyroidism Diseases 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 206010028665 Myxoedema Diseases 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 230000000903 blocking effect Effects 0.000 claims 3
- 208000003786 myxedema Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 2
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 2
- 208000003084 Graves Ophthalmopathy Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 229940122574 Thyroid-stimulating hormone receptor antagonist Drugs 0.000 claims 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 206010043778 thyroiditis Diseases 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 1
- 206010060742 Endocrine ophthalmopathy Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000772267 Homo sapiens Thyrotropin receptor Proteins 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000051345 human TSHR Human genes 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90133207P | 2007-02-15 | 2007-02-15 | |
| GB0702990A GB0702990D0 (en) | 2007-02-15 | 2007-02-15 | Products |
| GB0702990.3 | 2007-02-15 | ||
| US60/901,332 | 2007-02-15 | ||
| GB0714036.1 | 2007-07-18 | ||
| GB0714036A GB0714036D0 (en) | 2007-07-18 | 2007-07-18 | Products |
| PCT/GB2008/000518 WO2008099185A1 (en) | 2007-02-15 | 2008-02-14 | Human monoclonal antibodies to the thyrotropin receptor which act as antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010521139A JP2010521139A (ja) | 2010-06-24 |
| JP2010521139A5 true JP2010521139A5 (OSRAM) | 2010-08-19 |
| JP5345556B2 JP5345556B2 (ja) | 2013-11-20 |
Family
ID=42352063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549848A Active JP5345556B2 (ja) | 2007-02-15 | 2008-02-14 | アンタゴニストとして作用する、サイロトロピンレセプターに対するヒトモノクローナル抗体 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP5345556B2 (OSRAM) |
| CN (1) | CN101657468B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5997446B2 (ja) * | 2011-02-03 | 2016-09-28 | アークレイ株式会社 | 甲状腺ホルモン固定化担体の液体試薬およびその用途 |
| JP7025041B2 (ja) * | 2019-12-26 | 2022-02-24 | ヤマサ醤油株式会社 | 変異が導入された甲状腺刺激ホルモン受容体 |
| CN112269026A (zh) * | 2020-09-04 | 2021-01-26 | 首都医科大学附属北京朝阳医院 | 一种适用于tsh粉末状国际标准物质浓度准确配制的方法 |
| KR20250057832A (ko) * | 2022-08-31 | 2025-04-29 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 갑상선 자극 호르몬 수용체에 결합하는 항체 및 이의 용도 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9909661D0 (en) * | 1998-06-06 | 1999-06-23 | Rsr Ltd | Assays for TSH receptor autoantibodies |
| DE19907094C1 (de) * | 1999-02-19 | 2000-04-13 | Brahms Diagnostica Gmbh | Verwendung von blockierenden Anti-TSH-Rezeptor-Antikörpern bei der Therapie von Hyperthyreosen sowie monoklonale Antikörper für eine solche Verwendung |
| US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| JP5314234B2 (ja) * | 2002-11-29 | 2013-10-16 | アールエスアール リミテッド | チロトロピン受容体の結合対象及びその使用 |
-
2008
- 2008-02-14 CN CN200880011577.5A patent/CN101657468B/zh active Active
- 2008-02-14 JP JP2009549848A patent/JP5345556B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7332627B2 (ja) | 最適化された抗ｔｌ１ａ抗体 | |
| JP7046804B2 (ja) | 改良された血清アルブミン結合剤 | |
| US8999343B2 (en) | Antibodies that bind myostatin, compositions and methods | |
| TWI436778B (zh) | Ｉｌ－１８受體抗原結合蛋白 | |
| JP6224608B2 (ja) | 血液循環を安定化させるための、患者の急性疾患又は急性病態の治療法における使用に向けた、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP6193871B2 (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の臓器機能障害又は臓器不全を予防又は軽減するための、抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP2014525752A (ja) | 改変タンパク質およびペプチド | |
| CN105960414A (zh) | 治疗散发性包涵体肌炎的方法 | |
| JP2012518425A5 (OSRAM) | ||
| PT1888641E (pt) | Proteínas de ligação a albumina de soro | |
| TW201119675A (en) | Monoclonal antibodies to progastrin and their uses | |
| JP7461875B2 (ja) | 病気の症状の治療又は予防に使用するための抗アドレノメデュリン（ａｄｍ）バインダー | |
| JP2014533671A (ja) | 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| CN105358175B (zh) | 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法 | |
| TW201132759A (en) | Novel antagonist antibodies and their FaB fragments against GPVI and uses thereof | |
| JP2015502930A (ja) | 慢性若しくは急性疾患又は急性病態に罹患している患者の死亡リスクを低減するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP2017155050A (ja) | 慢性又は急性疾患に罹患している患者の体液平衡を調整するための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 | |
| JP2015518857A5 (OSRAM) | ||
| JP2010521139A5 (OSRAM) | ||
| CN116041513A (zh) | 靶向rankl的治疗性抗体 | |
| JP7489057B2 (ja) | 抗ポドカリキシン抗体 | |
| WO2023232003A1 (zh) | 抗HBsAg抗体及其应用 | |
| TW202323289A (zh) | 抗生長激素抗體 | |
| CN117586390A (zh) | 抗cgrp抗体及用途 | |
| HK40032645A (en) | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |